Cell and gene therapies
-
Patient dies in pricing stalemate
- 13 Nov 2023
As one man dies and another flies overseas for treatment, a former senior bureaucrat says States are not ready for cell and gene therapies.
Read more -
Gilead resubmits CAR T to MSAC
- 20 Oct 2023
Knocked back by the committee in March for use in the second-line setting, Gilead is set to try its luck again in 2024.
Read more -
Paperwork put before patient lives
- 13 Oct 2023
While a deal to fund Gilead’s second CAR-T is almost done, patients may well go to their deaths before the paperwork gets finalised.
Read more -
Gilead cuts price in secret deal
- 18 Sep 2023
Health Minister Mark Butler reveals his department has renegotiated the price for a cell therapy but the States are reluctant to come to the party.
Read more -
Aust lags in gene access, report finds
- 15 Sep 2023
Pfizer-commissioned ‘country scorecard’ looks at how fit-for-purpose Australia’s HTA is for gene therapies compared with other countries.
Read more -
Patients denied access to recommended CAR T
- 08 Sep 2023
Two years after MSAC recommended funding Gilead’s Tecartus for mantle cell lymphoma, patients are dying as funded access is rejected.
Read more -
States block third CAR-T application
- 23 Aug 2023
MSAC knocks back funding request citing strong opposition from NSW and Qld, who say cell therapies are failing to deliver on their promise.
Read more -
Genomics Australia launch delayed?
- 16 Aug 2023
Butler replaces Hunt’s committee with a new advisory body as Health says the launch of Genomics Australia will now likely be delayed.
Read more